

12
gnd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE **RECEIVED**

NOV 01 2002

TECH CENTER 1600/2900

In re PATENT APPLICATION OF

Anderson et al..

Group Art Unit: 1644

Application No. 09/874,141

Examiner: P. Gambel

Filed: June 6, 2001

Title: Non-Agonistic Antibodies to Human Gp39, Compositions Containing, and
Therapeutic Use Thereof

* * * * *


ELECTION

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action [Restriction Requirement] Applicants elect Group II with traverse. The traversal is in part, on the basis that Groups II, III and IV should be examined together, because of all these groups of claims are directed to use of anti-gp39 antibodies having a novel properly (non-agonistic) that renders them superior to anti-gp39 antibodies having agonistic properties.

Therefore, Applicants respectfully submit that claims 2-15 should be examined together.

By: 
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200
(703) 905-2500 Facsimile

Date: October 30, 2002